Consistent with the immune suppressive effects of TGF-β, treatments with TGF-β Trap control or BA led to increased tumour-associated CD8 T cells expressing the activation marker and immune checkpoint CTLA-4 (Fig. 3c). Here, CD8A is linked to neoplasm.